Monday, August 24, 2026 · Covering: Fri–Mon this weekend
TL;DR
The weekend belonged to Jackson Hole: Powell all but confirmed a September cut, saying the "shifting balance of risks may warrant adjusting our policy stance," and markets ripped — the S&P 500 jumped ~1.3% and September-cut odds spiked from ~72% to ~94%. Dealwise, the AI-infrastructure land grab kept rolling as Nvidia took a minority stake in data-center developer Cloverleaf Infrastructure, while strategics stayed acquisitive in consumer health (P&G/Thorne) and rare-disease biopharma (BioMarin/Alesta). Net: a dovish Fed plus cheaper money on the horizon is exactly the setup sponsors and corporates want heading into the fall deal season.
TOP 3 DEALS
DEAL 01 · TECH / TMT
Tech / TMT · AI Infrastructure
SIZEUndisclosed; WSJ reported several hundred $M
STRUCTUREMinority equity + strategic partnership (announced Aug 21)
INVESTORNvidia (advisors undisclosed)
TARGETCloverleaf Infrastructure (founded 2024)
Cloverleaf lines up the power, land and cooling that giant AI data centers need, and will deploy Nvidia's DSX platform to optimize site selection and buildout. The minority stake extends Nvidia's push beyond selling chips into owning slices of the physical infrastructure — power and real estate — that its GPUs ultimately depend on.
Why it matters for recruiting: The hottest theme in banking right now is "who finances and builds the AI grid." Minority strategic stakes like this are increasingly common — be ready to discuss why a chipmaker would invest upstream in power/data-center capacity (secure demand for GPUs, ease supply bottlenecks) and how bankers monetize the trend via project finance, infra M&A, and capital raises.
DEAL 02 · CONSUMER HEALTH / SPONSOR EXIT
Consumer Health · PE Exit
TRANSACTION VALUE$3.8B, all cash
STRUCTURESponsor-to-strategic sale, Q4 2026 close
BUYER ADVISORLegal: Jones Day (financial advisor undisclosed)
SELLER ADVISORSPerella Weinberg & Canaccord Genuity (for Thorne / L Catterton)
P&G is buying science-backed vitamins-and-supplements brand Thorne to ride the "wellness" and personalized-health wave, paying $3.8B in cash. For seller L Catterton, it's roughly a sixfold return on the ~$680M it paid to take Thorne private less than three years ago.
Why it matters for recruiting: A crisp sponsor-exit story with real advisor names to reference. Talk-track: why a consumer giant pays up for a fast-growing, higher-margin wellness brand (portfolio premiumization, shelf/scale synergies) and how a PE firm turns ~$680M into ~$3.8B in under three years (multiple expansion + growth, not leverage tricks).
DEAL 03 · HEALTHCARE / BIOPHARMA
Biopharma · Bolt-On
DEAL VALUE$275M upfront + up to $215M milestones
STRUCTUREShare purchase, Q3 2026 close (signed Aug 17)
BUYERBioMarin (advisors undisclosed)
TARGETAlesta Therapeutics (rare-disease pipeline)
BioMarin is buying Alesta for ALE1, a potential first-ever oral therapy for hypophosphatasia (a rare genetic bone disease), still in early clinical trials. The structure — modest cash upfront plus milestones tied to development progress — lets BioMarin buy a shot on goal without overpaying for an unproven asset.
Why it matters for recruiting: The perfect deal to explain earnouts/contingent value. Interviewers love asking how you'd value or model a milestone-laden biopharma deal — the answer involves risk-adjusting (probability-of-success weighting) future payments, which keeps the buyer's downside capped if the drug fails.
SECTOR SIGNAL
DEFENSE / AEROSPACE
A&D dealmaking stays centered on space, autonomy and AI; 2026 volume is tracking ~$32B, roughly matching last year. Recent marker still in play: TriMas selling its Aerospace segment to Blackstone and Tinicum for ~$1.5B. Source ↗
TECH / TMT
Nvidia's Cloverleaf stake is the latest sign the "AI-infrastructure" trade is bleeding into power and real estate, not just chips and models — expect more upstream strategic investments and infra financings. Source ↗
INDUSTRIALS / ENERGY
Data-center power demand keeps repricing anything tied to the grid — utilities, cooling, transmission and on-site generation are the new "picks and shovels," pulling infra-focused capital toward power assets. Source ↗
HEALTHCARE
Big pharma keeps doing small, milestone-heavy bolt-ons to refill pipelines — BioMarin/Alesta follows a summer of biopharma tuck-ins as buyers hunt de-risked assets rather than pricey platforms. Source ↗
M&A / LEVERAGED FINANCE
A dovish Powell is a green light for leveraged finance: lower base rates cut borrowing costs on floating-rate loans, improving LBO math and reopening the financing window into the fall. Private credit — now funding ~77% of LBOs by count — stands to benefit most, even as regulators watch late-cycle stress. Source ↗
MARKET TONE
Powell opens the door. At Jackson Hole he said the "shifting balance of risks may warrant adjusting our policy stance," signaling a September cut while promising to "proceed carefully." Source ↗
Markets cheered. The S&P 500 jumped ~1.3% on the speech as risk appetite snapped back after a jittery prior week. Source ↗
Odds re-priced fast. Futures-implied odds of a September cut leapt from ~72% to ~94%, teeing up the Fed's first cut since December 2024. Source ↗
But not a done deal. Powell flagged upside inflation risk and downside employment risk — a "challenging situation" — and nearly a month of data still lands before the Sept 17 meeting. Source ↗
Deal backdrop improving. Cheaper money plus resilient equity markets is the classic recipe for a busier fall M&A and financing calendar. Source ↗
INTERVIEW ANGLE
TOPIC: WHAT A FED CUT ACTUALLY DOES TO DEAL ACTIVITY
When an interviewer asks "how does a rate cut affect M&A?", don't just say "deals go up." Walk the mechanism — that's what separates a prepared candidate.
Cheaper leverage. Most LBO debt is floating-rate, priced off SOFR. A lower policy rate directly cuts interest expense, so a sponsor can support more debt (or a higher price) at the same coverage ratio — improving IRRs.
Higher valuations. Lower discount rates lift DCF values and expand acceptable purchase multiples, narrowing the bid-ask gap between buyers and sellers that has stalled deals.
Confidence + reopened windows. A clear easing path reduces uncertainty, which reopens the leveraged-loan and high-yield markets and emboldens boards to greenlight strategic deals.
The nuance. Cuts only help if they're not a response to a recession — a "dovish because the economy is fine" cut is bullish for deals; a "cutting because things are breaking" cut is not.
How to bring it up: "Powell's Jackson Hole pivot is a real tailwind for deal flow — cheaper floating-rate debt improves LBO returns and lower discount rates lift multiples, which should help close the bid-ask gap that's kept sponsors on the sidelines. The caveat is why the Fed is cutting; here it looks like insurance, not panic, which is the constructive version for M&A."